Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1991-09-12
1997-04-08
Stanton, Brian R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4351723, 536 231, A01N 4304, A61K 3170, C07H 2104, C12N 1506
Patent
active
056187963
ABSTRACT:
The present invention discloses novel methods and compositions useful for removing toxic heavy metals from a host organism containing detectable levels of such heavy metals. The method comprises administering to the host organism a therapeutically effective amount of a heavy-metal binding agent which, when saturated with heavy metal atoms, is readily excreted from the body. In a preferred embodiment of the present invention, the binding agent is an oligomeric phosphorothioate oligonucleotide.
REFERENCES:
patent: 5070104 (1991-12-01), Pariza
patent: 5276019 (1994-01-01), Cohen et al.
Westermann, "Inhibition of Expression of SV40 Virus Large T-Antigen by Antisense Oligodeoxyribonucleotides", Biomed.Biochim.Acta 48:1, 85-93 (1989).
James, "Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes", Antiviral Chemistry & Chemotherapy (1991) 2(4), 191-214.
Marshall, "Phosphorodithioate DNA as a Potential Therapeutic Drug", Science (1993) vol. 259, pp. 1564-1570.
Agrawal, "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc.Natl.Acad.Sci.USA, (1991) vol. 88, 7595-7599.
Uhlmann, "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews (1990) vol. 90, No. 4, 544-584.
M. Rothenberg et al., "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications", Journal of the National Cancer InstituT, issued 18 Oct. (1989) Commentary vol. 81, No. 20:pp.1539-1544.
Biochemistry, vol. 23, issued 1984, V.L. Pecoraro et al., "Stability Constants of Mg.sup.2+ and CD.sup.2+ Complexes of Adenine Nucleotides and Thionucleotides and Rate Constants for Formation and Dissociation of MgATP and MgADP", pp. 5262-5271, especially p. 5264.
Journal of the National Cancer Institute, vol. 81, No. 20, issued Oct. 18, 1989, M. Rothenberg et al., "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications", pp. 1539-1544, especially p. 1543.
Nature, vol. 299, issued Oct. 28, 1982, M. Karin et al., "Human Metallothionein Genes--Primary Structure of the Metallothionein-II Gene and a Related Processed Gene", pp. 797-802, especially p. 799.
Proceedings of the National Academy of Sciences, vol. 86, issued Jun. 1989, M. Matsukura et al., "Regulation of viral Expression of Human Immunodeficiency Virus in vitro by an Antisense Phosphorothioate Oligonucleotide Against rev (art/trs) in Chronically Infected Cells", pp. 4244-4248, especially p. 4245.
Toxicology, vol. 62, issued 1990, M. M. Jones et al., "The Search for Chelate Antagonists for Chronic Cadmium Intoxication", pp. 1-25, especially pp. 2, 6, 13, 19.
Marcus-Sekyra et al. 1987. Nucleic Acid Research 15(14): 5749-5763.
Kelley et al. 1988 Science 241: 1813-1815.
Iversen, 1991. Anti-cancer Drug Design 6:531-538.
Stanton Brian R.
The Board of Regents of the University of Nebraska
LandOfFree
Metal binding oligonucleotide and methods and compositions for t does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metal binding oligonucleotide and methods and compositions for t, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metal binding oligonucleotide and methods and compositions for t will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2397789